Why TG Therapeutics Stock Is Back in Focus
TG Therapeutics (TGTX) moved back onto investor radars after management lifted full year 2026 revenue guidance to about US$1b and reported detailed third quarter earnings on 9 November 2026.
Across 2026, TG Therapeutics has moved sharply higher, with the share price delivering a 120.49% year to date return and the 1-year total shareholder return at 108.53%, while the 3-year total shareholder return is very large at roughly 5x. This points to strong longer term momentum even after a recent 1-day share price decline of 1.82% and a last close of US$64.56.
Scan how TG Therapeutics compares with other fast moving biotech opportunities by checking our curated list of 20 high quality undiscovered gems aligned with strong fundamentals and under the radar momentum.
After a run this strong and fresh guidance around US$1b in 2026 revenue, TG Therapeutics now forces a choice: Is it worth paying up today, or does patience for a cleaner entry make more sense as the valuation section shows?
Most Popular Narrative: 17% Undervalued
The analyst consensus Narrative on Simply Wall St puts TG Therapeutics’ fair value at about $77.83 per share, compared with the recent $64.56 close. That gap reflects a view that current pricing does not fully capture the company’s earnings and cash generation potential under analysts’ assumptions.
The planned launch of subcutaneous BRIUMVI remains a key upcoming catalyst. It targets the 35 to 40% of the anti CD20 multiple sclerosis market that is currently in self administered products where TG Therapeutics does not yet participate, which could materially affect future revenue and earnings.
See why 75 investors see TG Therapeutics as 17% undervalued.
Analysts in that framework are working off a discount rate of about 7.7% and forecasting revenue expansion of roughly 27.8% a year with profit margins moving from 11.8% to around 32.7%. Those inputs help explain why a higher future earnings base and a projected P/E of 19.6x on 2029 earnings can still produce a fair value estimate above today’s share price.
The same Narrative also assumes earnings could reach about $612.2m by 2029 with fewer shares on issue, as buybacks reduce the count by an expected 4.17% per year over the next three years. That combination of margin expansion and lower share count feeds into higher earnings per share in the model and supports the view that TG Therapeutics is trading at a discount to its estimated future cash flow stream.
Result: Fair Value of $77.83 (UNDERVALUED)
Still, the TG Therapeutics story can change quickly if BRIUMVI expenses keep squeezing margins or if the fiduciary duty investigation escalates into distracting legal action.
Find out about the key risks to this TG Therapeutics narrative.
Another View: TG Therapeutics Looks Pricey On P/E
The DCF story presents TG Therapeutics as undervalued, yet the simple earnings multiple sends a very different message. The stock trades on an 85.3x P/E, compared with 50.5x for close peers and 15.9x for the broader US biotechs group, while the fair ratio stands at 31.6x. That gap points to valuation risk if enthusiasm cools.
For anyone weighing the trade-off between cash flow potential and a high headline multiple, it helps to see how the current P/E compares in detail with what the numbers suggest as a fair ratio, which you can do in our breakdown, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around TG Therapeutics can feel exciting and uncomfortable at the same time, so move quickly, review the evidence yourself, then weigh up the 3 key rewards and 2 important warning signs
Looking For More Investment Ideas Beyond TG Therapeutics?
If TG Therapeutics has your attention, do not stop here. Broaden your watchlist with other focused ideas that line up with the way you like to invest.
- Target potential bargains by scanning a curated set of quality businesses trading below estimated value through the 32 high quality undervalued stocks.
- Prioritise resilience by filtering for companies with robust finances and dependable fundamentals using the list of solid balance sheet and fundamentals (23 results).
- Lean into under the radar opportunities by tracking lesser known but fundamentally strong stocks with the 20 high quality undiscovered gems.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com